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Atherosclerotic cardiovascular disease is the worldwide leading cause of death, 
which involves multiple pathways in which lipoprotein entry and retention, injury to 
the vessel wall from several stimuli, and inflammation seem to play a key role. Cur-
rently available treatments are aimed at reducing the high plasma lipid concentrations, 
most particularly low density lipoprotein (LDL)-cholesterol. Increasing evidence has 
revealed that the concentration and size of the LDL particles are powerfully related 
to the degree of atherosclerosis progression than the concentration of cholesterol 
contained within all the LDL particles. LDL particles actually vary in size and density, 
and studies have shown that a pattern that has more small dense LDL particles—called 
“Pattern B”—equates to a higher risk factor for coronary heart disease (CHD) than 
does a pattern with more of the larger and less dense LDL particles (“Pattern A”). 
This is because the smaller particles are more easily able to penetrate the endothe-
lium. “Pattern I,” meaning “intermediate,” indicates that most LDL particles are very 
close in size to the normal gaps in the endothelium (26 nm). The healthiest pattern, 
though relatively rare, is to have small numbers of large LDL particles and no small 
particles. Having small LDL particles, though common, is an unhealthy pattern; high 
concentrations of small LDL particles (even though potentially carrying the same total 
cholesterol content as a low concentration of large particles) correlates with much 
faster growth of atheroma, progression of atherosclerosis and earlier and more severe 
cardiovascular disease events and death.
Statin therapy has improved free-events survival, lowering LDL-cholesterol and 
controlling inflammation. Unfortunately, cardiovascular events continue to occur de-
spite LDL-lowering therapy. This is probably due to the fact that there are risk factors 
that are important in certain patients other than LDL-cholesterol. Therefore there is a 
clear need for additional preventive and therapeutic interventions to complement the 
results of LDL lowering. Among others increased level of high density lipoprotein-
cholesterol (HDL-C) is thought to protect against atherosclerosis by promoting the 
efflux of excess cholesterol from cells and returning that cholesterol to the liver for 
secretion into the bile, but depends on the repeated transfer of cholesteryl esters among 
lipoproteins before final the excretion occurs through the liver. Interestingly, during 
the last years investigators have explored the effect of inflammatory stimuli on the 
formation of a phenotype of HDL with reduced anti-atherogenicity, suggesting a link 
between inflammation and HDL functionality. One such target for new interventions is 
HDL and/or its apolipoproteins. HDL and/or its apolipoproteins have been recognized 
to have major vascular protective effects ranging from prevention to stabilization and 
regression. The relationship between low levels of HDL-C and the development of 
coronary heart disease can be inferred from epidemiological studies, were even small 
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differences in the level of HDL-C are associated with substan-
tial variations in the risk of major coronary events. Data from 
the Framingham population indicated that at any given level 
of total cholesterol, the relative risk of CAD increases with 
decreasing levels of HDL-C. Low HDL-cholesterol is com-
monly found in the general population. For example, 18% of 
men and 4% of women in the Framingham Offspring study 
had HDL-cholesterol equal or below 35 mg/dl. 
The Veterans Affairs cooperative studies program High 
density Intervention Trial (VA-HIT) assessed the effect of 
raising HDL-C levels on coronary heart disease risk in patients 
with low levels of both LDL-C and HDL-C. After 1-year with 
gemfibrozil treatment there a significant effect on HDL-C and 
total cholesterol but not LDL-C; which was associated with a 
reduction of 22 % in non-fatal myocardial infarction or death 
due to coronary heart disease, compared to placebo therapy. 
For every 5 mg increase in HDL-C, there was a decrease in 
CHD-death or myocardial infarction by 11 %. Furthermore, 
the PROCAM and the Helsinki Heart studies suggest that a 
high ratio of triglyceridemia/HDL cholesterol constitutes a 
powerful risk factor for fatal or non-fatal myocardial infarc-
tion that would escape attention if LDL cholesterol levels 
alone were determined. Dietary and exercise modifications 
can lead to improvement to HDL-C concentrations, which 
may be associated with greater antioxidantive role of HDL-
C. Kesteloot et al, in a Belgian population group investigated 
the relationship between dietary fat intake and serum total 
and HDL-cholesterol and revealed that polyunsaturated fat 
and the polyunsaturated/saturated-ratio decrease the HDL-
C value, while dietary cholesterol increased the HDL-C level 
in women only, alcohol consumption increased and cigarette 
smoking decreased HDL-C levels, demonstrating the impor-
tance of dietary fat as a determinant of the serum lipid level 
within a population. The key lifestyle changes to increase 
HDL-C are weight loss in the case of obesity, increased 
physical activity, smoking cessation and alcohol consumption 
in moderate amounts. With smoking cessation for example, 
HDL-C increases on average 6–8 mg/dl. 
Ezetimibe is a new selective cholesterol absorption inhibi-
tor that blocks the uptake of dietary and biliary cholesterol by 
preventing its transport through the intestinal wall, without 
affecting the passage of other fat-soluble nutrients. Ezetimibe 
can reduce LDL-C-levels by up to 1% and moderately 
increases HDL-C by 3.5%; while it is well tolerated when 
administered with a statin or fibrate with additive effects. 
A combination of lovastatin plus extended release niacin, 
currently in clinical development, has been demonstrated to 
produce greater effects on LDL-C, HDL-C and triglyceride 
levels than either of the two drugs alone; HDL-C-levels were 
increased by 30%, LDL-C decreased by 47%. However, cu-
taneous flushing resulted in the withdrawal of 7% of patients 
from the study. Another very interesting therapeutic approach 
is the infusion of apolipoprotein A-I, the main apolipoprotein 
of HDL. This approach seems to lead also to an increase of 
reverse cholesterol transport and regression of atherosclerosis 
in animal models.
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